The Department of Health has prepared an Essential Drugs List (EDL) for public sector implementation in 1996 and future extension to the private sector.
Stakeholders have been consulted to ensure that the EDL achieves its objectives of safety, efficacy and quality at the lowest possible cost, while providing coverage for 90 - 95% of the common and important conditions in the country.
This study was undertaken to gain insight into the current use of EDL products by 200 general practitioners (GPs) servicing a large health maintenance organisation (HMO).
Approximately 120 000 prescriptions were reviewed and the use of specified EDL medicines, other forms of EDL medicines and non-EDL medicines was analysed for several pharmacological groups.
These included antibiotics and medicines for the cardiovascular, musculoskeletal, central nervous, respiratory and gastrointestinal systems.
To gauge potential savings to the private sector through the purchase of EDL products at state tender prices, current paces of a random sample of EDL products were compared.
In the areas reviewed, only 22.4% of current GP prescriptions included EDL items ; a further 19.6% included'other forms of EDL'items.
Simply obtaining those EDL products that are currently prescribed at state tender prices would reduce costs by almost 20%, while extending the use of EDL products might save in excess of 70% on private sector GP prescriptions.
Mots-clés Pascal : République Sud Africaine, Afrique, Liste, Médicament, Prescription, Secteur privé, Médecin, Pratique professionnelle, Etude comparative, Economie santé, Coût
Mots-clés Pascal anglais : South Africa, Africa, List, Drug, Prescription, Private sector, Physician, Professional practice, Comparative study, Health economy, Costs
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0493324
Code Inist : 002B02A07. Création : 10/04/1997.